We have two other anti-inflammatory programs with potential application in large markets: zeaxanthin for macular degeneration and hepatic disease; and lycophyll for prostate disease. Both of these product platforms have potential to be developed first as dietary supplements and later as drugs.

We plan additional research and development to select the optimal zeaxanthin and lycophyll compositions and formulations for dietary supplement and/or drug development through our own capabilities or through a strategic alliance or a manufacturing agreement.